|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 23, 2020 ) Report Overview:
[135 Pages Report] Lung cancer surgery is an operation performed for treating lung cancer, particularly non-small cell lung cancer. This study of the lung cancer surgery market primarily pertains to the lung cancer surgical devices market. Surgical procedures are covered separately in this report, as part of the lung cancer surgical procedures market.
The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The major factors driving the growth of this market are increasing incidence and prevalence of lung cancer, rapid growth in the aging population, and growing healthcare expenditure worldwide. On the other hand, high cost of lung cancer surgeries is the major factor that is expected to restrain the growth of this market during the forecast period.
Technological Advancements in Lung Cancer Treatment
Currently, robot-assisted surgery, minimally invasive surgeries (such as video-assisted thoracoscopic surgeries), and percutaneous trans-catheter surgeries (such as radiofrequency ablation and cryo ablation) are some of the advanced surgical procedures that are used in the treatment of lung cancer. As compared to conventional open surgeries, these advanced procedures offer various advantages such as shorter hospital stay, shorter chest tube duration, less blood loss, and smaller incisions. As a result, the preference for these procedures is higher among patients as well as surgeons. Considering the implications of these technological advancements on patient safety, patient comfort, and surgical outcomes, the demand for technologically advanced approaches for the treatment of lung cancer is expected to increase in the coming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222
Opportunity: Untapped Emerging Markets
Emerging markets, such as China, India, and Brazil, offer significant growth opportunities for players operating in the lung cancer surgery market. These countries are expected to witness high growth in the coming years, owing to the presence of less stringent regulatory policies and low competition. Moreover, the growing prevalence of lung cancer is expected to increase the number of lung cancer surgeries in these emerging markets. According to GLOBOCAN, in 2015, the total incidence of lung cancer in emerging markets such as China, India, and Brazil was around 0.84 million and this figure is expected to reach 0.9 million by 2020. As a result of increasing disposable incomes, the healthcare expenditure in these economies is increasing rapidly. Between 2003 and 2012, growth rates for healthcare expenditure in Asia and the RoW were 11.2% and 13.9%, respectively. According to estimates from the World Bank, healthcare spending in India increased from 4.3% of GDP in 2005 to 4.7% of GDP in 2015. Additionally, growing purchasing power has enabled the patient population in emerging countries to opt for technologically advanced medical services and solutions. This in turn is expected to drive the demand for advanced medical devices, including minimally invasive surgery products, in these countries.
Key Market Players:
Ethicon US LLC (U.S.), Intutive Surgical Inc. (U.S.), Olympus Corporation (Japan), Accuray Inc. (U.S.) and Teleflex Inc. (U.S.).
Inquiry about lung cancer surgery market before buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=222
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
